Surgeon and biotech billionaire Patrick Soon Shiong has sold pancreatic cancer patients on a 'Bioshield' immunotherapy program he describes as a personal mission, but the only drug in his commercial portfolio, Anktiva, is approved for bladder cancer, and the FDA has called the…
In a June 18 STAT+ column, biotech columnist Adam Feuerstein argues that billionaire surgeon Patrick Soon-Shiong has spent years selling pancreatic cancer patients on an immunotherapy promise he has not delivered. The argument lands hardest in pancreatic cancer specifically because Soon-Shiong has tied the disease to his own medical biography, and because the only drug in his commercial portfolio carries a label for a different organ entirely.
The treatment at the center of the dispute is Anktiva, an immune-stimulating drug made by ImmunityBio, the company Soon-Shiong founded and controls. Anktiva's FDA approval covers a narrow bladder cancer indication, specifically a non-muscle-invasive form of the disease in patients whose tumors stopped responding to the standard BCG therapy. The drug has no approved pancreatic cancer indication, and the company's promotional language about pancreatic cancer has drawn a formal regulatory rebuke.
On March 13, 2026, the FDA sent ImmunityBio a warning letter calling a TV ad and a podcast "false and misleading." According to STAT's Pharmalot column, the agency cited implied "all cancers" efficacy, an omitted requirement that Anktiva be used in combination with a bacterial vaccine, downplayed safety risks, and unsupported "cancer free" claims. The letter puts a documented floor under the gap between the marketing and the evidence.
The pancreatic-cancer record is the most pointed example of a longer pattern. In a September 2025 STAT column, Feuerstein found that the lung cancer survival data Soon-Shiong cited did not support the claims he was making in promotional settings. In January 2026, STAT reported that Soon-Shiong had publicly mischaracterized the outcome of an in-person FDA meeting on Anktiva. The FDA, the outlet's sources said, had earlier refused to file a submission that would have broadened Anktiva's bladder-cancer label because the underlying data were inconclusive.
Soon-Shiong frames the work as a personal mission. On ImmunityBio's "Founder's Vision" page, he describes a "Bioshield" program built around his own history as a transplant and pancreatic-cancer surgeon, and his belief that activating the immune system can defeat solid tumors. The page is the canonical statement of the thesis: an umbrella for multiple tumor types, anchored to Soon-Shiong's biography and rolled out in promotional venues that go well beyond the published evidence.
For patients and readers, the most useful response is not to argue about Soon-Shiong's motives, which the public record cannot settle, but to apply a short checklist to any billionaire-physician's cancer announcement. The first question is whether the claim sits inside the drug's approved indication or is an off-label promotional assertion. The second is which trial produced the supporting data, what the endpoint was, and whether the result has cleared peer review. The third is what regulators have actually said in writing, and where the FDA correspondence can be read. The fourth is whether a real survival curve is available, or only a press-release summary of one. The fifth is who is funding the science, and whether the named spokesperson has a financial stake in the answer.
Anktiva is approved, in a narrow population, for a specific kind of bladder cancer. Its creator's pancreatic-cancer claims are not. The FDA has now put that gap in writing. The next cure announcement from any named physician-entrepreneur deserves to be read against the same record.